Abstract-Hypertension is considered a low-grade inflammatory condition, and understanding the role of transcription factors in guiding this response is pertinent. A prominent transcription factor that governs inflammatory responses and has become a focal point in hypertensive research is nuclear factor-B (NFB). Within the hypothalamic paraventricular nucleus (PVN), a known brain cardioregulatory center, NFB becomes potentially even more important in ultimately coordinating the systemic hypertensive response. To definitively demonstrate the role of NFB in the neurogenic hypertensive response, we hypothesized that PVN NFB blockade would attenuate angiotensin II-induced hypertension. Twelve-week-old male Sprague-Dawley rats were implanted with radiotelemetry probes for blood pressure measurement and allowed a 7-day recovery. After baseline blood pressure recordings, rats were administered either continuous NFB decoy oligodeoxynucleotide infusion or microinjection of a serine mutated adenoviral inhibitory-B vector, or their respective controls, bilaterally into the PVN to inhibit NFB at two levels of its activation pathway. Simultaneously, rats were implanted subcutaneously with an angiotensin II or saline-filled 14-day osmotic minipump. After the 2-week treatments, rats were euthanized and brain tissues collected for PVN analysis. Bilaterally inhibited NFB rats had a decrease in blood pressure, NFB p65 subunit activity, proinflammatory cytokines, and reactive oxygen species, including the angiotensin II type 1 receptor, angiotensin-converting enzyme, tumor necrosis factor, and superoxide in angiotensin II-treated rats. Moreover, after NFB blockade, key protective antihypertensive renin-angiotensin system components were upregulated. This demonstrates the important role that transcription factor NFB plays within the PVN in modulating and perpetuating the hypertensive response via renin-angiotensin system modulation. ypertension is a condition closely associated with the renin-angiotensin system (RAS) and increased expression of proinflammatory cytokines (PICs) and reactive oxygen species (ROS), in both systemic and local hypertensive responses. [1][2][3][4][5][6] Studies from our laboratory and others have shown that, in hypertension, angiotensin II (Ang II), PICs, and ROS can increase the activity of the transcription factor nuclear factor-B (NFB), which, in turn, can further increase PIC and ROS expression in a positive feed-forward manner. 5,[7][8][9][10] Within the brain, multiple cardioregulatory regions exhibit a local RAS, including the hypothalamic paraventricular nucleus (PVN), which can synthesize and release both prohypertensive and antihypertensive RAS component peptides. 2,11,12 The PVN is widely recognized as a central integration site for the coordination of autonomic and neuroendocrine responses that regulates thirst, salt appetite, and sympathetic outflow. [13][14] [15] Ang II is a large peptide that cannot cross the blood-brain barrier (BBB). Therefore, it exerts its roles by acting on the circumventricular organs, where the BBB is either weak or absent. 16, 17 Signals from these circumventricular organs subsequently activate neurons within the various cardioregulatory centers of the hypothalamus and brain stem, including the PVN, 17 which can respond by locally producing components of the RAS and via sympathetic signals to the periphery. 5 Findings from our laboratory and others have shown that, in hypertension, PICs are increased within discrete brain sites, such as the PVN, and that signals from both the systemic and local RASs increase PICs and oxidative stress. 5, 18 Within the PVN, RAS components, PICs, and ROS have been linked to increased sympathoexcitation and perpetuation of the hypertensive state. 19, 20 Based on the preceding evidence, we hypothesized that bilateral PVN blockade of NFB would attenuate these observed regional changes, which propagate the Ang II-induced hypertensive response, including increases in PICs and ROS. To test this hypothesis, we blocked NFB within the PVN using two approaches: bilateral PVN NFB decoy oligodeoxynucleotide infusion or bilateral PVN microinjection of an adenoviral vector containing a serine mutated inhibitory-B (IB; AdIB) insert. 
H ypertension is a condition closely associated with the renin-angiotensin system (RAS) and increased expression of proinflammatory cytokines (PICs) and reactive oxygen species (ROS), in both systemic and local hypertensive responses. [1] [2] [3] [4] [5] [6] Studies from our laboratory and others have shown that, in hypertension, angiotensin II (Ang II), PICs, and ROS can increase the activity of the transcription factor nuclear factor-B (NFB), which, in turn, can further increase PIC and ROS expression in a positive feed-forward manner. 5, [7] [8] [9] [10] Within the brain, multiple cardioregulatory regions exhibit a local RAS, including the hypothalamic paraventricular nucleus (PVN), which can synthesize and release both prohypertensive and antihypertensive RAS component peptides. 2, 11, 12 The PVN is widely recognized as a central integration site for the coordination of autonomic and neuroendocrine responses that regulates thirst, salt appetite, and sympathetic outflow. [13] [14] [15] Ang II is a large peptide that cannot cross the blood-brain barrier (BBB). Therefore, it exerts its roles by acting on the circumventricular organs, where the BBB is either weak or absent. 16, 17 Signals from these circumventricular organs subsequently activate neurons within the various cardioregulatory centers of the hypothalamus and brain stem, including the PVN, 17 which can respond by locally producing components of the RAS and via sympathetic signals to the periphery. 5 Findings from our laboratory and others have shown that, in hypertension, PICs are increased within discrete brain sites, such as the PVN, and that signals from both the systemic and local RASs increase PICs and oxidative stress. 5, 18 Within the PVN, RAS components, PICs, and ROS have been linked to increased sympathoexcitation and perpetuation of the hypertensive state. 19, 20 Based on the preceding evidence, we hypothesized that bilateral PVN blockade of NFB would attenuate these observed regional changes, which propagate the Ang II-induced hypertensive response, including increases in PICs and ROS. To test this hypothesis, we blocked NFB within the PVN using two approaches: bilateral PVN NFB decoy oligodeoxynucleotide infusion or bilateral PVN microinjection of an adenoviral vector containing a serine mutated inhibitory-B (IB; AdIB) insert. These techniques block separate locations in the NFB transcription activation pathway. Our results demonstrate that blocking NFB attenuates hypertension through a reduction of PIC and ROS actions within the PVN. NFB also appears to mediate the balance between the prohypertensive and the antihypertensive arms of the RAS. These data indicate that PVN-specific NFB plays a role in controlling hypertension through increased PICs and ROS via RAS modulation.
Materials and Methods

Animals
Male Sprague-Dawley rats (12 weeks old, 250 -350 g) were used in this study. Animals were housed in a temperature-(25Ϯ1°C) and light-controlled (12:12-hour light:dark cycle) room with free access to water and normal rat chow (0.4% salt content). All of the animal procedures were reviewed and approved by the Louisiana State University Institutional Animal Care and Use Committee in accordance with National Institutes of Health guidelines.
Experimental Protocol
All of the experimental rats were anesthetized and implanted with radiotelemetry transmitters. After a 7-day recovery, bilateral cannulae were placed into the PVN. Fourteen-day osmotic minipumps (ALZET, model 2002; infusion rate of 0.5 L/h) were filled with Ang II (Bachem, 200 ng/kg per minute) dissolved in 0.9% saline, or saline alone, and implanted subcutaneously in the retroscapular area. Simultaneously, osmotic minipumps (ALZET, model 1004; infusion rate of 0.11 L/h) were filled with NFB decoy or control scrambled decoy oligodeoxynucleotide (2 ng/kg per minute; Sigma), dissolved in artificial cerebrospinal fluid (aCSF), implanted subcutaneously in the retroscapular area and connected to the cannula. The NFB decoy concentration was determined from a previous pilot study in rats using 3 different doses, 200 pg/kg per minute, 2 ng/kg per minute, and 200 ng/kg per minute. The 2 ng/kg per minute dose was found to be optimal, whereas the highest dose caused increased mortality and the lowest dose did not produce complete NFB inhibition as measured using an NFB (p65) activity assay. Rats were divided into 4 groups: (1) no treatment (controls; nϭ11); (2) saline minipump ϩ bilateral PVN NFB decoy (salineϩNFB decoy; nϭ18); (3) Ang II minipump ϩ bilateral PVN scrambled decoy (Ang IIϩscramble decoy; nϭ18); and (4) Ang II minipump ϩ bilateral PVN NFB decoy (Ang IIϩNFB decoy; nϭ20). To determine the potential effect of NFB decoy leakage into the brain's ventricular system, rats (nϭ7) were administered intracerebroventricularly (ICV) the same dose (2 ng/kg per minute) at the same flow rate.
Another group of rats were injected (2ϫ10 10 pfu/mL, 100 nL) bilaterally intra-PVN with an adenoviral vector (Ad) containing IB serine mutated at the S23A/S36A positions (AdIB) or a control Ad with an empty cassette region (AdEmpty; both adenoviruses obtained from Gene Transfer Vector Core, University of Iowa, Carver College of Medicine) using a 1-L Hamilton syringe, as described previously. 12, 21 Fourteen-day osmotic minipumps (ALZET, model 2002; 0.5 L/h) were filled with Ang II dissolved in 0.9% saline or saline alone and simultaneously implanted subcutaneously into the retroscapular area. These rats were divided into 4 groups: (1) no treatment (controls; nϭ10); (2) saline minipump ϩ bilateral PVN AdIB (salineϩAdIB; nϭ19); (3) Ang II minipump ϩ bilateral PVN AdEmpty (Ang IIϩAdEmpty; nϭ18); and (4) Ang II minipump ϩ bilateral PVN AdIB (Ang IIϩAdIB; nϭ21). A final group of rats was treated with Ang II alone (nϭ15) and used for Western blot, immunohistochemical, and electron paramagnetic resonance analysis. After 14 days of blood pressure recordings, rats were euthanized using a high ketamineϩxylazine dose, and brain tissue was collected for mRNA and protein analysis. Blood plasma was used to determine circulating norepinephrine (NE) via highperformance liquid chromatography. Rats that received treatment unilaterally into the PVN or had malfunctioning pumps (ie, tube detachment from pump or cannula, based on postmortem analysis) were excluded from the final analysis (success rate: bilateral cannulation, Ϸ78%; bilateral microinjection, Ϸ65%). Chow salt content did not appear to have any effect on pressure response. A PϽ0.05 was considered statistically significant. An expanded Methods section can be found in the online Data Supplement, available at http://hyper.ahajournals.org.
Results
NFB Blockade in the PVN Reduces p65 Subunit Binding Activity
The PVN was bilaterally infused with NFB decoy oligodeoxynucleotide via a fixed cannula ( Figure 1A ) or bilaterally microinjected with an adenovirus encoding serine mutated IB to overexpress IB and inhibit NFB within the PVN. Localization of injection sites of all rats are schematically represented in Figure S1 (please see the online Data Supplement at http://hyper.ahajournals.org), with those receiving unilateral or no treatment excluded from the subsequent final analyses. The localization of IB gene overexpression specifically within the PVN after bilateral PVN AdIB microinjection was indicated by enhanced IB fluorescence (Figures 1B and S2A ). To determine the efficacy of the two methods of inhibiting NFB activity, an NFB p65 subunit activity assay was conducted after the PVN 14-day treatments. The p65 subunit activity was dramatically increased in the PVN in the two Ang II-treated groups versus their respective controls ( Figure 1C ). This increase in activity was attenuated in both Ang IIϩNFB decoy and Ang IIϩAdIB-treated rats. However, p65 subunit activity was unaltered in the lateral hypothalamus of any group ( Figure S2B ), indicating that the effect of NFB and its blockade was localized to the PVN and not the surrounding regions. These data show that NFB is increased within the PVN during Ang IIinduced hypertension and that the use of NFB decoy or AdIB can potently, and site specifically, inhibit NFB activity.
NFB Blockade in the PVN Attenuates the Ang II-Induced Blood Pressure Response
Chronic 14-day Ang II infusion significantly increased the mean arterial pressure (MAP) in rats that received scramble decoy or AdEmpty treatment versus their respective salineinfused controls (salineϩNFB decoy and salineϩAdIB; Figure 2 ). Conversely, the MAP of Ang IIϩNFB decoy and Ang IIϩAdIB rats had a significantly reduced MAP from their Ang II-treated counterparts, although the MAP was not normalized. Rats receiving either treatment unilaterally, while showing a reduced MAP versus the Ang II control groups, were not reduced as effectively as bilateral treatments ( Figure S3 ), indicating compensation from the untreated side of the PVN. Furthermore, Ang IIϩICV NFB decoy-treated rats had a slightly, although not significantly, reduced MAP versus the Ang IIϩscramble decoy group ( Figure S3A ), demonstrating that the potential effect from ventricle decoy leakage on additional central cardioregulatory sites is minimal. These data indicate that PVN NFB plays an important role in regulating blood pressure response in Ang II-induced hypertension.
NFB Blockade Decreases PIC Expression in the PVN
Ang II infusion significantly increased the mRNA expression of tumor necrosis factor-␣ (TNF), interleukin-1B (IL-1␤), IL-6, and the chemokine monocyte chemotactic protein (MCP)-1 in the PVN versus control rats. However, bilateral PVN NFB decoy infusion or bilateral microinjection of AdIB into the PVN attenuated these changes in PIC gene expression ( Figure 3A) . Furthermore, immunohistochemistry against TNF showed an increased staining in Ang II-treated rats (Ang II alone) versus controls (no treatment; Figures 3B and S4). This protein expression was reduced via bilateral PVN NFB decoy infusion or bilateral AdIB microinjection into the PVN, demonstrating that, through bilateral PVN NFB inhibition, PIC levels are reduced within this hypothalamic region.
NFB Blockade Effects RAS Component Expression in the PVN
Ang II infusion significantly increased the mRNA expression of the prohypertensive Ang II type 1 receptor (AT 1 R) and angiotensin-converting enzyme (ACE) in the PVN when compared with control rat groups and decreased the antihypertensive ACE2 and MasR expression versus their respective control groups ( Figure 4A ). Bilateral NFB decoy infusion or microinjection of AdIB into the PVN reversed these gene expression changes. Ang II also decreased the Mas/AT 1 R ratio within the PVN, which was reversed in Ang IIϩNFB decoy and Ang IIϩAdIB groups ( Figure S5A ). These results were further confirmed for AT 1 R and MasR protein levels in the PVN by Western blot ( Figure 4B ) and densitometric ( Figure S5B and S5C) analysis. These results show that NFB plays a modulatory role in differential RAS Representative immunofluorescence image for inhibitory-B (IB) is localized in the PVN after adenoviral IB (AdIB) bilateral microinjection into control rat. C, NFB p65 activity assay showing increased activity in the PVN of the angiotensin II (Ang II)-treated groups when compared with control groups. p65 activity is decreased in Ang II-treated rats after bilateral PVN NFB decoy infusion or AdIB microinjection. nϭ5 to 6 per group, *PϽ0.05 vs respective Ang II-treated rats, #PϽ0.05 vs respective control-treated rats. 
NFB Blockade Reduces ROS Production in the PVN
Total ROS, superoxide (O 2
•Ϫ ), and peroxynitrite (OONO • ) levels were significantly increased in the PVN of Ang II-treated rats (Ang II alone) versus controls (no treatment; Figure 5 ). These ROS levels were decreased to normal after chronic bilateral NFB decoy infusion or AdIB microinjection into the PVN, indicating the role that NFB plays in increasing ROS during the hypertensive response.
NFB Blockade Increases Neuronal NO Synthase Expression in the PVN and Decreased Circulating Plasma NE
Neuronal NO synthase (nNOS) expression is an indirect indicator of neuronal activity. In Ang II-treated rat groups, nNOS mRNA was significantly decreased when compared with the control groups ( Figure 6A ). Bilateral NFB decoy infusion or AdIB microinjection into the PVN reversed and elevated these Ang II-induced changes above that of the normotensive controls. These results were further confirmed with immunohistochemistry against nNOS ( Figures 6B and  S6A) , where Ang II-infused rats (Ang II alone) had decreased nNOS presence versus controls (no treatment), which was reversed by NFB blockade. Furthermore, plasma NE was increased in Ang II-treated rats when compared with controls, but normalized after bilateral NFB decoy infusion or AdIB microinjection into the PVN ( Figure S6B ). These results indicate that NFB within the PVN potentially augments neuronal activity and sympathoexcitation and that NFB inhibition within this region can attenuate these Ang II-induced hypertensive changes.
Discussion
In the present study, we investigated the effects of bilateral hypothalamic PVN-specific blockade of NFB on the Ang II-induced hypertensive response. The salient findings of this study are as follows: (1) peripheral Ang II infusion increases MAP, which is attenuated by bilateral PVN NFB blockade; 
Expression is decreased after bilateral PVN NFB decoy infusion or adenoviral inhibitory-B (AdIB) microinjection (nϭ6 -8 per group). B, Immunohistochemical staining for TNF is increased in the PVN in Ang II-infused rats (Ang II alone) vs controls (no treatment).
Staining was decreased after NFB decoy infusion or AdIB microinjection in rats treated bilaterally intra-PVN. Representative images from preparations of 5 to 6 rats. *PϽ0.05 vs respective Ang II-treated rats, #PϽ0.05 vs respective control-treated rats.
(2) peripheral Ang II infusion increases PICs, ROS, and prohypertensive (ACE and AT 1 R) RAS components and decreases the antihypertensive (ACE2 and Mas) RAS components within the PVN; (3) bilateral PVN-specific NFB inhibition of Ang II-infused rats not only decreases PVN PICs but also modulates RAS component expression, such as decreasing ACE and AT 1 R expression and increasing ACE2 and MasR expression; (4) PVN blockade of NFB leads to an increase in nNOS expression and a decrease in superoxide, peroxynitrite, and circulating NE levels. These results indicate that bilateral PVN NFB blockade decreases the deleterious prohypertensive RAS arm and increases the protective antihypertensive RAS arm, possibly through an ROSmediated mechanism, thereby attenuating the Ang II-induced hypertensive response. On stimulation, NFB is released after IB phosphorylation, ubiquination, and degradation, freeing NFB and allowing its nuclear translocation to act on B binding sites and commence transcription. 22 In this study, two approaches were used to block NFB within the PVN. AdIB binds to NFB similar to endogenous IB, but serine mutations at the S32A/S36A position prevent IB phosphorylation and the ensuing NFB release, thereby inhibiting its capability to translocate into the nucleus and transcribe target genes. 22 Decoy oligodeoxynucleotides act by targeting and adhering to the cis-element binding sites of free NFB, preventing its attachment to B binding sites and blocking subsequent gene transcription. 23, 24 By blocking NFB at two separate activation pathway locations, it effectively demonstrates the role of PVN NFB in Ang II-induced hypertension and potentially signifies that there are no secondary pathways activated between NFB/IB release and its nuclear translocation/ binding. Previous findings from our laboratory investigating the role of the PVN in Ang II-induced hypertension demonstrated that NFB within the PVN was differentially regulated along with PIC and oxidative stress genes and proteins. 5 This work presented the involvement of brain NFB in regulating the hypertensive response, a previously novel proposal. However, ICV infusion of pyrrolidine dithiocarbamate, a known antioxidant, 25 was used to study NFB in the PVN, signifying that NFB and its subsequent actions could have been reduced through an antioxidant-driven mechanism rather than through direct NFB intervention. Also, because of ICV administration, we could not rule out the possible involvement of other affected cardioregulatory regions for the observed reduction in the hypertensive response. Therefore, the exact role and proposed involvement/ mechanism of NFB within the PVN remains uncertain. The current study looks at NFB blockade specifically within the PVN in the Ang II-induced hypertensive response, delineates the involvement of PVN NFB in regulating ROS and PIC expression and, perhaps more importantly, shows that NFB serves as a potential tipping point between the injurious prohypertensive and protective antihypertensive RAS axes within the PVN. Extensive evidence implicates the RAS within the brain in hypertension. 2, 12, 26, 27 In the PVN, Ang II is increased in multiple hypertensive models, and PVN blockade of the AT 1 R partially inhibits the effects of Ang II-induced hypertension. 5,14,26 -28 The association between the RAS and elevated PICs in hypertension has often been explored. 1, 15, 19, 20 NFB is a key regulator of the PIC expression and inflammatory response observed in hypertension. 5, 8, 34 Here, we show that bilateral NFB inhibition in the PVN reduces PIC expression, establishing not only the definitive involvement of NFB within the PVN in regulating the Ang II-induced hypertensive pressure response, but also that PICs may play a role in RAS modulation. Recently, ROS, especially O 2
•Ϫ , have been shown as important signaling factors within the brain for enhancement of the neurogenic hypertensive response through both Ang II and PIC mechanisms. 9, 10, 35 Here, bilateral NFB blockade reduced the ROS response, including O 2
•Ϫ , thus potentially inhibiting one of the mechanistic pathways by which the hypertensive response and sympathoexcitation (as indicated by decreased plasma NE), is modulated. These results are further confirmed by previous experiments in our laboratory showing that ICV administration of the ROS scavenger, Tempol, reduced renal sympathetic nerve activity in Ang II-treated rats. 5 This shows that PVN-specific NFB blockade reduces the PIC and ROS reactions typically associated with Ang IIinduced hypertension and highlights the central position that PVN NFB plays in regulating the neurogenic component of hypertension.
Sympathoexcitation is a component of hypertension, and increased levels of Ang II in the central nervous system and PVN can enhance sympathetic outflow through increased ROS, AT 1 R, and NE activation and a subsequent downregulation of nNOS. 4,36 -39 The expression and presence of nNOS, an indirect indicator of neuronal activity and downstream sympathetic activity, is inversely proportional to the level of sympathetic outflow, 40 -42 and NO, a well known sympathoinhibitory neurotransmitter, when blocked, results in elevated MAP and sympathoexcitation. 37, 43 Furthermore, increased superoxide can interact with the decreasing nNOS-produced NO, forming OONO
• , further reducing NO bioavailability and resulting in enhanced sympathoexcitation. 44 Recently, Ang(1-7) and MasR activation have been shown to increase nNOS activity and NO release. 45 The current study shows that, after Ang II treatment, nNOS is decreased within the PVN, potentially indicating increased sympathetic outflow. Also, bilateral NFB inhibition decreased elevated Ang II-induced OONO
• . This OONO • decrease paralleled that of O 2
•Ϫ and was concurrent with the nNOS increase, indicating that NFB potentially plays a deciding role in regulating NO availability and sympathoexcitation. These results were reinforced by circulating NE, which was normalized in Ang II-infused rats after bilateral NFB blockade. Therefore, bilateral NFB inhibition increased nNOS and reduced O 2
•Ϫ , OONO • , and plasma NE, possibly through balancing RAS components, and thus potentially reducing sympathoexcitation.
In conclusion, this study shows that after the Ang II activation of the prohypertensive RAS arm, PICs are increased, which separately and together, can act to increase the activity of NFB and lead to the transcription of additional prohypertensive modulators in a positive feed-forward manner. NFB acts to increase, along with Ang II, the presence of ROS, such as O 2
•Ϫ , which subsequently affects the present NO levels, thereby effecting neuronal activity/function and NE release. Blockade of NFB at two separate locations in its activation pathway prevents these changes, restores the RAS balance, and promotes the antihypertensive RAS arm, including ACE2 and the MasR. It also reduces PIC and ROS expression and elevates nNOS, all of which contribute to a reduction in MAP and an improvement in the Ang II-induced hypertensive state. However, this signaling mechanism must be further studied to delineate the manner by which NFB and O 2
•Ϫ interact within the PVN in Ang II-induced hypertension. We propose that Ang II activation of NFB increases PICs and O 2
•Ϫ , tipping the balance of the RAS in favor of the prohypertensive arm and decreasing the antihypertensive arm, resulting in a further increase in PIC and ROS expression, in a vicious positive feed-forward mechanism ( Figure  S7 ). Limitations for this study include the use of the Ang II hypertensive model, because this does not represent all modes of hypertension. Also, we only explored the PVN region, although there are multiple cardiorelevant sites in the brain that can play a role in modulating the hypertensive response; however, we feel that the PVN is of importance because of its recognized integrative functions. Moreover, as the literature suggests, adenoviruses are well known for their lack of cell specificity and can be expressed by neurons and glia and participate in retrograde transport. 46 For this reason, we used NFB decoy oligodeoxynucleotides to further verify our results. Thus, in the current clinical environment where novel hypertensive therapeutic measures are continuously being sought, this study provides a conceptual basis for including NFB inhibitors that can specifically act within the brain as a possible future pharmacological approach for the treatment of hypertension.
Perspectives
Increasing evidence indicates that central nervous system mechanisms play an important role in the pathogenesis of cardiovascular disease. In this study, we demonstrate that inflammatory molecules, specifically, transcription factor
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NFB, within the PVN, can modulate the hypertensive response.
In addition, we demonstrate that inflammation is a double-edged weapon that not only upregulates the deleterious prohypertensive RAS axis but also downregulates the protective antihypertensive RAS axis. Thus, inflammatorymediated modulation of the brain RAS might be an important critical contributor to neurogenic hypertension. Because inflammation and the RAS are potent inducers of oxidative stress and NFB has been shown to respond to and induce oxidative stress, it may be advantageous to target NFB to better treat hypertension. Although the current methods used within this study are impractical for current clinical administration, one can explore the use of NFB small molecule inhibitors that cross the blood-brain barrier, thereby targeting the brain's source of inflammation and oxidative stress, for controlling and treating this debilitating condition.
